Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ZAP70 interaction with 13 mRNAs as a potential immunotherapeutic target for endometrial cancer. | Oncol Lett | 2023 | 37123018 | PubTator, text mining | PubMed |
| Hairy Cell Leukemia: Where Are We in 2023? | Curr Oncol Rep | 2023 | 37097545 | PubTator, text mining | PubMed |
| Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial. | Neurol Neuroimmunol Neuroinflamm | 2023 | 37094998 | PubTator, text mining | PubMed |
| Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma. | Expert Rev Hematol | 2023 | 37086394 | PubTator, text mining | PubMed |
| Editorial: The immune escape mechanism and novel immunotherapeutic strategies of leukemia. | Front Immunol | 2023 | 37081892 | PubTator, text mining | PubMed |
| Clinical and Cytogenetic Characterization, and Outcome of Chronic Lymphocytic Leukemia Patients in a Single Tertiary Center in Saudi Arabia. | Clin Hematol Int | 2023 | 37081205 | PubTator, text mining | PubMed |
| Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial. | Clin Cancer Res | 2023 | 37074726 | PubTator, text mining | PubMed |
| Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. | Nat Commun | 2023 | 37072421 | PubTator, text mining | PubMed |
| 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. | iScience | 2023 | 37063467 | PubTator, text mining | PubMed |
| Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study. | Front Oncol | 2023 | 37056335 | PubTator, text mining | PubMed |
| A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine. | Cell Death Discov | 2023 | 37055391 | PubTator, text mining | PubMed |
| Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia. | J Clin Med | 2023 | 37048814 | PubTator, text mining | PubMed |
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2023 | 37046657 | PubTator, text mining | PubMed |
| Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions. | Front Oncol | 2023 | 37035197 | PubTator, text mining | PubMed |
| Precision diagnostics in chronic lymphocytic leukemia: Past, present and future. | Front Oncol | 2023 | 37035166 | PubTator, text mining | PubMed |
| Editorial: Role of the antigen receptor in the pathogenesis of B-cell lymphoid malignancies. | Front Oncol | 2023 | 37035146 | PubTator, text mining | PubMed |
| A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial. | Blood Adv | 2023 | 37026799 | PubTator, text mining | PubMed |
| Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization. | Proc Natl Acad Sci U S A | 2023 | 37011197 | PubTator, text mining | PubMed |
| A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL. | Front Med (Lausanne) | 2023 | 37007770 | PubTator, text mining | PubMed |
| Structural and immunological basis of cross-reactivity between dengue and Zika infections: Implications in serosurveillance in endemic regions. | Front Microbiol | 2023 | 37007463 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=19